Kim Nguyen, PhD
Kim Nguyen, PhD, is the chief technical officer of Affini-T Therapeutics. She has over 15 years of experience leading technical development and operations teams in the cell and gene therapy field. Prior to Affini-T, Kim served as vice president of CMC at Precision BioSciences.
Loïc Vincent, PhD
Loïc Vincent, PhD, is chief scientific officer at Affini-T Therapeutics. He is an oncology scientist with 20+ years’ international experience in academia/biotech/pharma industry, dedicated to advancing transformative therapies to patients suffering from cancer.
Kathy Yi, MBA
Kathy Yi, MBA., is the chief operations officer of Affini-T Therapeutics. She has served as a member of Theseus Pharmaceuticals board of directors since June 2021.
Phil Greenberg, MD
Phil Greenberg, MD, is head of immunology at the Fred Hutchinson Cancer Research Center. He is an internationally-recognized expert in cancer immunotherapy. His early discoveries targeting diseases with immune T cells helped drive this rapidly expanding field.
Aude Chapuis, MD
Aude Chapuis, MD, is associate professor of immunology in the Clinical Research Division at the Fred Hutchinson Cancer Research Center. She is an expert in blood stem cell transplantation and immunotherapy.
Tom Schmitt, PhD
Dr. Tom Schmitt, PhD, is scientific co-founder and associate of clinical research at Fred Hutchinson Cancer Research Center. He works on improved T-cell therapies with his team.
Chris Klebanoff, MD
Jim Allison, PhD
Jim Allison, PhD, is regental professor and executive director of the Immunotherapy Platform, at University of Texas MD Anderson Cancer Center. He has spent a storied career studying the regulation of T cell responses and developing strategies for cancer immunotherapy.
Pam Sharma, MD, PhD
Padmanee “Pam” Sharma, MD, PhD, professor of genitourinary medical oncology and immunology, co-director for immunotherapy at University of Texas MD Anderson Cancer Center. She is a leading cancer immunotherapy translational scientist.